Business
Posting of Annual Report & Accounts and AGM Notice
Posting of Annual Report & Accounts and AGM Notice.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \nRNS Number : 0835L Avacta Group PLC 07 January 2016 \n\n7 January 2016\n \nAvacta Group plc\n(\"Avacta\" or the \"Group\")\n \nPosting of Annual Report & Accounts and AGM Notice\n \nAvacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, confirms that the Annual Report and Accounts for the year ended 31 July 2015, the Notice of the Annual General Meeting and a Form of Proxy were posted to shareholders on 30 December 2015.\n \nThe Annual General Meeting is to be held on Monday 25 January 2016 at 2.00pm GMT at the offices of Walker Morris, Kings Court, 12 King Street, Leeds, LS1 2HL.\n \nA copy of the Annual Report & Accounts and Notice of Annual General Meeting is available on the Company's website: www.avacta.com. \n \nEnquiries:\n \n\n\n\n\nAvacta Group plc\nAlastair Smith, Chief Executive Officer\nTony Gardiner, Chief Financial Officer\n\n\nTel: +44 (0) 844 414 0452\nwww.avacta.com\n\n\n\n\n \n\n\n \n\n\n\n\nNumis Securities Limited \nMichael Meade / Freddie Barnfield - Nominated Adviser\nJames Black - Corporate Broking\n\n\nTel: +44 (0) 207 260 1000\nwww.numiscorp.com\n\n\n\n\n \n\n\n \n\n\n\n\nMedia Enquiries\nFTI Consulting\nSimon Conway/Natalie Garland-Collins\n \n\n\nTel: +44 (0) 20 3727 1000 [email protected]\n \n \n\n\n\n\nNotes to Editors\n \nAvacta Group plc (www.avacta.com)\n \nAvacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.\n \nAntibodies dominate markets worth in excess of $50bn despite their shortcomings. The Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. The Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets. \n \nAvacta has a pre-clinical biotech development programme with an in-house focus on oncology and bleeding disorders as well...